ClinicalTrials.gg
Active, not recruitingNCT04754035IMPROVEUpdated Oct 3, 2023

Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

A Phase 2 interventional study of Venetoclax and Imbruvica Oral Product in Chronic Lymphocytic Leukemia, sponsored by Paolo Ghia. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-03.

Sponsored by Paolo Ghia · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
54th of 69
31 · median 72
Started
2017
with 3 others
Phase 2
41 of 69
16 open now
Primary completion
2018-07
later than 0 of 41 live
Registered
21st of 69
by date
Lead sponsor
3 of 69
Paolo Ghia

Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 54th largest by planned enrollment, is one of 4 that started in 2017, is one of 41 in phase 2, reaches primary completion later than 0 of the 41 other live ones, and was the 21st registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is a Phase 2a, multicenter, open-label uncontrolled study aimed at determining therapeutic benefits of the addition of ibrutinib to venetoclax in patients with relapsed/refractory CLL based on a MRD-guided approach.

Read the detailed description

Venetoclax will be administered, initially as single agent, orally once daily (QD), starting with 20 mg on Day 1, followed by weekly dose escalation up to 400 mg, if well tolerated [Ramp-up Period, according to the modified Venetoclax schedule in Phase 2 and 3 clinical trials] and continued thereafter. At Cycle 12 Day 1, disease status, renal function and risk of bleeding will be assessed. Minimal residual disease (MRD) in the peripheral blood will be evaluated in patients with CR or PR by flow cytometry. All MRD negative subjects (defined as those with MRD level in the PB \<10-4 in the PB and in the BM aspirate) will discontinue venetoclax at the end of Cycle 12 (i.e. Cycle 12 Day 28). All MRD positive subjects (defined as those with MRD level in the PB >10-4) and patients with stable disease without any contraindications to ibrutinib treatment will continue venetoclax and start treatment with ibrutinib at the standard dose for CLL of 420 mg QD. Venetoclax will be administered until unacceptable toxicity or disease progression or for a maximum of 2 years and ibrutinib will be continued until unacceptable toxicity, confirmed MRD negativity, or disease progression.

MRD will be assessed every 3 months starting 3 months after treatment initiation; MRD negativity at Cycle 12 Day 1 will be evaluated in PB BM aspirate.

Patients experiencing clinical disease progression will discontinue study treatment and will be followed up for survival status and subsequent anti-cancer therapy.

Inclusion criteria 1. Documented CLL requiring treatment according to the IWCLL criteria (Hallek et al. 2008) 2. Relapsed/refractory CLL patients who received at least 1 prior therapy 3. Adequate bone marrow function without transfusion \< 2 weeks of screening as follows:

a. Absolute neutrophil count (ANC) ≥1.0 x 109/L (growth factors administration is allowed) b. Platelets ≥30 x 109/L. If thrombocytopenia due to BM involvement, platelets should be ≥ 20 x 109/L c. Hemoglobin value ≥8.0 g/dl exclusion criteria

  1. Transformation of CLL to aggressive NHL (Richter's transformation or pro-lymphocytic leukemia)
  2. Known central nervous system (CNS) involvement
  3. Inadequate renal function: CrCl \<30 mL/min
  4. Previous treatment with BTK and/or BCL2 inhibitors (patients previously treated with PI3K inhibitors are eligible)
  5. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia
  6. Requires the use of warfarin, marcumar, or phenprocoumon (potential drug-drug interaction increasing exposure of warfarin or phenprocoumon): low molecular weight drugs e.g. heparin are acceptable
  7. Treatment, administration or consumption of any of the following within 3 days prior to the first dose of venetoclax (see also Appendix G).

    1. Strong Cytochrome P450 3A (CYP3A) inhibitors
    2. Moderate CYP3A inhibitors
    3. Moderate or strong CYP3A inducers
    4. PI3K inhibitors (e.g. Idelalisib);
    5. Grapefruit or grapefruit products
    6. Seville oranges (including marmalade containing Seville oranges)
    7. Star fruit
  8. Known history of human immunodeficiency virus (HIV) or active with hepatitis B virus (HBV) or hepatitis C virus (HCV). Subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.
  9. History of other malignancies, except:

    1. Malignancy treated with curative intent and with no known active disease present for ≥3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    3. Adequately treated carcinoma in situ without current evidence of disease.

Updated International Workshop on CLL (IWCLL, Hallek et al. 2008) criteria will be used to determine rates of response and progression for patients with CLL with the modification to exclude lymphocytosis as an isolated criterion of progression in patients treated with agents inhibiting B-cell receptor signaling.

The primary endpoint objective response rate (MRD negativity) as well as secondary efficacy endpoints (e.g. ORR, PR, CR, PFS) will be derived from Investigator assessment.

Patients who reach a complete and partial response, as per standard criteria, will be investigated using MRD testing for molecular response categories as described in IWCLL.

The safety and tolerability of study drug treatments will be evaluated by means of AEs (incidence and severity), performance status, physical examinations, 12-lead resting electrocardiograms (ECGs), and laboratory safety evaluations.

Laboratory and AE toxicities will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.

biomarker assessment

  • Whole exome sequencing on leukemic samples before, during and after treatment and/or at relapse in order to dissect mechanisms of resistance.
  • High-throughput sequencing for MRD detection
  • Biochemical assays on the circulating leukemic population during ibrutinib treatment to study activation of signaling pathways.

Statistical considerations According to optimal Simon Two-Stage Phase 2 design, with the null hypothesis (P0) of a MRD-negative CR at 12 months of 5%, this study will consider a satisfactory efficacy of the venetoclax + ibrutinib combination worth of further investigation a P1 corresponding to a MRD-negative CR of 30%. Considering a standard type I error (α) of 0.05 and a power of 95%, 29 MRD positive patients will be necessary for the expansion phase of the trial. A first step analysis will be implemented when 9 MRD positive patients have been enrolled and study will proceed to complete the planned accrual if at least 1/9 patients will obtain a MRD negative CR at 12 months after starting Ibrutinib. Considering that 5% of patients are expected to reach a MRD negative CR with venetoclax alone, the target population to be enrolled into the trial is 31 patients.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age
  2. Documented CLL requiring treatment according to the IWCLL criteria (Hallek M et al, 2008)
  3. CLL patients who received at least 1 prior therapy
  4. Adequate bone marrow function without transfusion \< 2 weeks of screening as follows:

    1. (ANC) ≥1.0 x 109/L (growth factors administration is allowed)
    2. ≥30 x 109/L. If thrombocytopenia due to BM involvement, platelets should be ≥ 20 x 109/L
    3. value ≥8.0 g/dl
  5. The patient has adequate renal and hepatic function per local reference laboratory reference ranges as follows:

    1. Renal: patient has a (CrCl) ≥ 30 mL/min
    2. Hepatic: and ALT ≤ 3 × the upper normal limit () of institution's normal range and ≤ 1.5 × ULN. Patients with AIHA and Gilbert's syndrome may have a bilirubin > 1.5 × ULN, but these conditions must be clearly documented in clinical records.
  6. Female patients of and non-sterile male patients must practice at least one of method of with partner(s) beginning with initial treatment administration and continuing to 30 days after the last dose of study treatment. Female of child bearing potential must have a negative serum pregnancy test upon study entry
  7. Male patient must agree to refrain from sperm donation, from initial treatment administration until 90 days after the last dose of treatment
  8. Ability to provide written and to understand and comply with the requirements of the study

Exclusion criteria

Exclusion criteria

  1. Transformation of CLL to aggressive NHL (Richter's transformation or pro-lymphocytic leukemia)
  2. Known central nervous system (CNS) involvement
  3. Inadequate renal function: \<30 mL/min
  4. Previous treatment with BTK and/or BCL2 inhibitors (patients previously treated with PI3K inhibitors are eligible)
  5. Uncontrolled hemolytic anemia or immune thrombocytopenia
  6. Requires the use of warfarin, marcumar, or phenprocoumon (potential drug-drug interaction increasing exposure of warfarin or phenprocoumon): low molecular weight drugs e.g. heparin are acceptable
  7. Treatment, administration or consumption of any of the following within 3 days prior to the first dose of venetoclax (see also Appendix G):

    1. Strong Cytochrome P450 3A () inhibitors
    2. Moderate CYP3A inhibitors
    3. Moderate or strong CYP3A inducers
    4. PI3K inhibitor (e.g. Idelalisib);
    5. Grapefruit or grapefruit products
    6. Seville oranges (including marmalade containing Seville oranges)
    7. Star fruit
  8. Known history of (HIV) or active with virus (HBV) or virus (HCV). Subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.
  9. Known to one or more study drugs
  10. Known bleeding disorders (e.g. von Willebrand's disease) or hemophilia
  11. History of stroke or intracranial hemorrhage within 6 months prior to enrollment
  12. Major surgery within 4 weeks of the first dose of study drug
  13. Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach, or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction
  14. Any uncontrolled active systemic infection or infection requiring systemic treatment that was completed ≤7 days before planned treatment start date
  15. Prior stem cell transplant
  16. Lactating or pregnant
  17. Unable to understand the purpose and the risks of the study and to provide a signed and dated (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations)
  18. History of other , except:

    1. Malignancy treated with curative intent and with no known active disease present for ≥3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    3. Adequately treated carcinoma in situ without current evidence of disease.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    venetoclax + ibrutinib

    Drug: Venetoclax · Drug: Imbruvica Oral Product

Interventions

06

What researchers measure

Primary outcomes

  1. Minimal residual disease

    Minimal residual disease (MRD) negativity rate evaluated by multi-colour flow cytometry analysis (limit of detection 10-4) within the treatment period

    Time frame: 4 years

Secondary outcomes

  1. Complete response (CR) rate

    Time frame: 4 years

  2. Progression-free survival (PFS) rate at 12 months

    Time frame: 1 year

  3. Progression Free Survival (PFS)

    Time frame: 4 years

  4. Overall response rate (ORR)

    Time frame: 4 years

  5. Duration of response (DOR)

    Time frame: 4 years

  6. Overall Survival (OS);

    Time frame: 4 years

  7. Adverse events

    Type, frequency, and severity of adverse events (AEs) and relationship of AEs

    Time frame: 4 years

  8. Proportion of premature withdrawals

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Publications

  • Scarfo L, Heltai S, Albi E, Scarano E, Schiattone L, Farina L, Moia R, Deodato M, Ferrario A, Motta M, Reda G, Sancetta R, Coscia M, Rivela P, Laurenti L, Varettoni M, Perotta E, Capasso A, Ranghetti P, Colia M, Ghia P. Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL. Blood. 2022 Dec 1;140(22):2348-2357. doi: 10.1182/blood.2022016901. PubMed 35921541 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jul 2018, 8 months.

Of 207 non-industry phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's 8 months is below that.

Counting every sponsor, half of 248 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2017
First posted
Feb 15, 2021
StartActual
Nov 8, 2017
Primary completionActual
Jul 31, 2018
CompletionEst.
Sep 1, 2025
Last update
Oct 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04754035
Lead sponsor
Paolo Ghia
Responsible party
Paolo Ghia (Principal Investigator, IRCCS San Raffaele) — Sponsor-investigator
First posted
Feb 15, 2021
Start date
Nov 8, 2017
Primary completion
Jul 31, 2018
Completion
Sep 1, 2025 (estimated)
Last update
Oct 3, 2023

Study contacts

Paolo Ghia, Prof
study chair · San Raffaele Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion